Clavulanate (potassium salt) (Synonyms: BRL 14151K) |
| Katalog-Nr.GC15637 |
β-lactamase inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 61177-45-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Clavulanate is a metabolite existed in cultures of Streptomyces clavuligerusa with activity against both Gram-positive and Gram-negative bacteria. Clavulanate is a first clinically useful broad-spectrum β-lactamase inhibitor. Clavulanate formulations have been widely used in the treatment of a broad range of clinical infections [1].
Clavulanate was least active against Pseudomonas spp. and the enterococci with MICs of 125–512 mg/L, followed by members of the Enterobacteriaceae and H. influenzae with MICs of 12–125 mg/L. Clavulanate showed great activity against Bacteroides spp. and other anaerobes, M. catarrhalis, staphylococci and streptococci with MICs of 4–50 mg/L. Clavulanate was active against Neisseria spp. with MICs of 1.25–4 mg/L [1].
In an infection model of L. pneumophila pneumonia leucopenic weanling rats, clavulanate effectively prevented the development of infection. In a mouse lethal thigh infection model with two susceptible strains of S. pneumoniae, treatment with clavulanate decreased the mortality [1].
Reference:
[1] Finlay J, Miller L, Poupard J A. A review of the antimicrobial activity of clavulanate[J]. Journal of Antimicrobial Chemotherapy, 2003, 52(1): 18-23.
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *